je.st
news
Tag: cardiovascular
TECOS, Mercks Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes
2015-06-08 22:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Findings Published in the New England Journal of Medicine and Presented at the American Diabetes Association Scientific Sessions Treatment with Sitagliptin Did Not Increase the Risk of Major Adverse Cardiovascular Events in the Primary Composite Endpoint, or Hospitalization for Heart Failure, Compared with Placebo KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), a placebo-controlled study of the cardiovascular (CV) safety of Mercks DPP-4 inhibitor, JANUVIA (sitagliptin), added to usual care in more than 14,000 patients. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Media Capsule: Please Activate Javascript !function(d, s, id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https',dt=new Date().getTime();if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+"://s3.amazonaws.com/contentcapsule.com/clients/Merck/tags/d5542d85-2f26-45dc-b64c-3ee84a4312ff_reg_frame.js?dt="+dt;fjs.parentNode.insertBefore(js,fjs);}}(document,"script","contentcapsule-embed-d5542d85-2f26-45dc-b64c-3ee84a4312ff"); Ticker Slug: Ticker: MRK Exchange: NYSE read more
Digisonics Showcases Latest Offerings for Cardiovascular Information System Solutions at ASE 2015
2015-06-04 12:31:09| Industrial Newsroom - All News for Today
HOUSTON Digisonics (Booth #922), a leading provider of cardiovascular information system solutions will showcase its latest offerings at this years American Society for Echocardiography Annual Scientific Sessions in Boston, Mass. The Business Analytics Package, a new application for productivity and automation...
Tags: information
system
latest
solutions
Digisonics Wins Bid to Provide Stillwater Medical Center with a Cardiovascular Information System (CVIS)
2015-04-28 12:31:13| Industrial Newsroom - All News for Today
HOUSTON Digisonics is proud to announce that after a competitive bid process, it has been awarded the contract to provide a Cardiovascular Information System (CVIS) to Stillwater Medical Center in Stillwater, Okla., for their echo, nuclear, vascular and cardiac catheterization studies. An added web-based...
Tags: information
system
provide
center
Merck Announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Met Primary Endpoint
2015-04-27 23:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) of Mercks DPP-4 inhibitor, JANUVIA (sitagliptin), achieved its primary endpoint of non-inferiority for the composite cardiovascular (CV) endpoint. Among secondary endpoints, there was no increase in hospitalization for heart failure in the sitagliptin group versus placebo. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestor:Joe Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: met
primary
trial
outcomes
Broad Institute expands collaboration with Bayer to develop new cardiovascular therapies
2015-03-31 12:57:29| Chemicals - Topix.net
The Broad Institute of MIT and Harvard have expanded their collaboration with Bayer HealthCare to include cardiovascular genomics and drug discovery. The goal of this new part of the alliance is to leverage insights from human genetics to help create new cardiovascular therapies.
Tags: develop
institute
broad
collaboration
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] next »